Aptamers as therapeutics.
TL;DR: A series of aptamers currently in development may change how nucleic acid therapeutics are perceived and will increasingly find use in concert with other therapeutic molecules and modalities.
read more
Abstract: Nucleic acid aptamers can be selected from pools of random-sequence oligonucleotides to bind a wide range of biomedically relevant proteins with affinities and specificities that are comparable to antibodies. Aptamers exhibit significant advantages relative to protein therapeutics in terms of size, synthetic accessibility and modification by medicinal chemistry. Despite these properties, aptamers have been slow to reach the marketplace, with only one aptamer-based drug receiving approval so far. A series of aptamers currently in development may change how nucleic acid therapeutics are perceived. It is likely that in the future, aptamers will increasingly find use in concert with other therapeutic molecules and modalities.
read more
Chat with Paper
AI Agents for this Paper
Find similar papers on Google Scholar, PubMed and Arxiv
Write a critical review of this paper
Analyze citations of this paper to find unaddressed research gaps
Citations
Cancer Nanotechnology: The impact of passive and active targeting in the era of modern cancer biology
TL;DR: The fundamental concepts of enhanced permeability and retention effect (EPR) are revisited and the mechanisms proposed to enhance preferential "retention" in the tumor, whether using active targeting of nanoparticles, binding of drugs to their tumoral targets or the presence of tumor associated macrophages are explored.
2.6K
Aptamers as targeted therapeutics: current potential and challenges
Jiehua Zhou,John J. Rossi +1 more
TL;DR: This Review discusses challenges of clinical translation of therapeutic aptamers, highlighting recent clinical developments and technological advances that have revived the impetus for this promising class of therapeutics.
1.7K
Targeted polymeric therapeutic nanoparticles: design, development and clinical translation
TL;DR: In this critical review, insights are provided into the design and development of targeted polymeric NPs and the challenges associated with the engineering of this novel class of therapeutics are highlighted, including considerations of NP design optimization, development and biophysicochemical properties.
A Molecular Imaging Primer: Modalities, Imaging Agents, and Applications
TL;DR: This review of molecular imaging of intact living subjects focuses specifically on small molecules, peptides, aptamers, engineered proteins, and nanoparticles and cites examples of how molecular imaging is being applied in oncology, neuroscience, cardiology, gene therapy, cell tracking, and theranostics.
1K
The chemical evolution of oligonucleotide therapies of clinical utility.
TL;DR: As oligonucleotides with a particular chemical design show appropriate distribution and safety profiles for clinical gene silencing in a particular tissue, this will open the door to the rapid development of additional drugs targeting other disease-associated genes in the same tissue.
993
References
Cell-specific aptamers for targeted therapies.
TL;DR: The most recent advances in the field will be reviewed together with detailed descriptions of the relevant experimental approaches to raise aptamers against living cells.
Automated selection of anti-protein aptamers.
J. Colin Cox,Andrew D. Ellington +1 more
TL;DR: The in vitro selection of nucleic acid binding species (aptamers) is frequently repetitive, time-consuming, and poorly adapted to high-throughput applications as discussed by the authors ; however, the increases in throughput brought about by automation should potentiate the application of aptamer technology to the rapidly growing field of proteomics.
Escort aptamers: a delivery service for diagnosis and therapy
Brian Hicke,Andrew W. Stephens +1 more
TL;DR: A new development is discussed: the use of “escort aptamers” as targeting agents for invivo diagnosis and therapy, designed to deliver benignuclides, toxins, or cytotoxic agents to diseased tissue.
Selection, characterization and application of new RNA HIV gp 120 aptamers for facile delivery of Dicer substrate siRNAs into HIV infected cells
Jiehua Zhou,Piotr Swiderski,Haitang Li,Jane Zhang,C. Preston Neff,Ramesh Akkina,John J. Rossi +6 more
TL;DR: A series of new dual inhibitory function anti-gp120 aptamer–siRNA chimeras are created and a ‘sticky’ sequence is introduced onto a chemically synthesized aptamer which facilitates attachment of the Dicer substrate siRNAs for potential multiplexing.
Novel Approach to Specific Growth Factor Inhibition in Vivo : Antagonism of Platelet-Derived Growth Factor in Glomerulonephritis by Aptamers
Jürgen Floege,Tammo Ostendorf,Ulf Janssen,Burg M,Heinfried H. Radeke,Chandra Vargeese,Stanley C. Gill,Louis S. Green,Nebojsa Janjic +8 more
TL;DR: Data show that specific inhibition of growth factors using custom-designed, high-affinity aptamers is feasible and effective in mesangial cells and on the natural course of the disease.